79 related articles for article (PubMed ID: 9236055)
1. Pneumococcal vaccination: four issues for western Europe.
Fedson DS
Biologicals; 1997 Jun; 25(2):215-9. PubMed ID: 9236055
[No Abstract] [Full Text] [Related]
2. Preventing pneumococcal disease.
Thomas R
Can Fam Physician; 1998 Oct; 44():2180-1, 2184-5. PubMed ID: 9805173
[No Abstract] [Full Text] [Related]
3. [Cost-effectiveness of pneumococcal vaccination of the elderly].
Hak E; Grobbee DE; Verheij TJ
Ned Tijdschr Geneeskd; 1998 Jan; 142(4):201-2; author reply 202-3. PubMed ID: 9557028
[No Abstract] [Full Text] [Related]
4. Childhood vaccination against pneumococcal otitis media and pneumonia: an analysis of benefits and costs.
Weycker D; Richardson E; Oster G
Am J Manag Care; 2000 Jul; 6(10 Suppl):S526-35. PubMed ID: 11183904
[TBL] [Abstract][Full Text] [Related]
5. Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.
Hubben GA; Bos JM; Glynn DM; van der Ende A; van Alphen L; Postma MJ
Vaccine; 2007 May; 25(18):3669-78. PubMed ID: 17360082
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands.
Postma MJ; Heijnen ML; Beutels P; Jager JC
Expert Rev Vaccines; 2003 Aug; 2(4):477-82. PubMed ID: 14711333
[TBL] [Abstract][Full Text] [Related]
8. [Cost-effectiveness of pneumococcal vaccination in the elderly].
van den Berg JW
Ned Tijdschr Geneeskd; 1998 Jan; 142(4):202-3. PubMed ID: 9557029
[No Abstract] [Full Text] [Related]
9. [Vaccination of the elderly against pneumococcal disease is cost-efficient. Mass vaccination of all aged 65 and over is recommended].
Ortqvist A; Jönsson B; Baltussen R; Ament A
Lakartidningen; 2000 Nov; 97(45):5120-5. PubMed ID: 11116891
[TBL] [Abstract][Full Text] [Related]
10. [An antipneumococcal vaccination program for the elderly of Bologna].
Roveri P; Faggioli A; Gianninoni AR; Agostini D
Ann Ig; 1999; 11(4):319-27. PubMed ID: 10520525
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries.
Ament A; Baltussen R; Duru G; Rigaud-Bully C; de Graeve D; Ortqvist A; Jönsson B; Verhaegen J; Gaillat J; Christie P; Cifre AS; Vivas D; Loiseau C; Fedson DS
Clin Infect Dis; 2000 Aug; 31(2):444-50. PubMed ID: 10987703
[TBL] [Abstract][Full Text] [Related]
12. Otitis media: prospects for prevention.
Haggard M
Vaccine; 2008 Dec; 26 Suppl 7():G20-4. PubMed ID: 19094934
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps.
Vold Pepper P; Owens DK
Clin Infect Dis; 2000 Jan; 30(1):157-64. PubMed ID: 10619745
[TBL] [Abstract][Full Text] [Related]
14. [The elderly should be vaccinated against pneumococci].
Ortqvist A; Hedlund J; Kalin M
Lakartidningen; 1999 Mar; 96(11):1305-8. PubMed ID: 10194909
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden.
Bergman A; Hjelmgren J; Ortqvist A; Wisløff T; Kristiansen IS; Högberg LD; Persson KM; Persson U
Scand J Infect Dis; 2008; 40(9):721-9. PubMed ID: 18712627
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
Melegaro A; Edmunds WJ
Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy.
Marchetti M; Colombo GL
Vaccine; 2005 Aug; 23(37):4565-76. PubMed ID: 15992969
[TBL] [Abstract][Full Text] [Related]
18. Probabilistic sensitivity analysis in cost-effectiveness. An application from a study of vaccination against pneumococcal bacteremia in the elderly.
Whang W; Sisk JE; Heitjan DF; Moskowitz AJ
Int J Technol Assess Health Care; 1999; 15(3):563-72. PubMed ID: 10874382
[TBL] [Abstract][Full Text] [Related]
19. Lifesaving opportunities missed: the challenge of vaccinating older Americans for pneumococcal diseases and influenza.
Tschantz K; Foley LA
Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2000 Oct; (IB45):1-9. PubMed ID: 11885591
[No Abstract] [Full Text] [Related]
20. [Pneumococcal vaccination; arguments for informing parents about the options available].
Beaujean DJ; Verweij MF; van Steenbergen JE
Ned Tijdschr Geneeskd; 2005 Apr; 149(17):909-11. PubMed ID: 15884402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
